Compare iShares MSCI China ETF (MCHI) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Koninklijke Philips NV — how do they compare? iShares MSCI China ETF trades at $52.8 (market cap $6.00B), while Koninklijke Philips NV trades at $24.38 (market cap $23.68B). The key difference: Koninklijke Philips NV is far larger — about 3.9× iShares MSCI China ETF's market cap, and Koninklijke Philips NV pays a 4.21% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and Koninklijke Philips NV for 84 Days on average.
| MCHI | PHG | |
|---|---|---|
Market Cap | $6.00B | $23.68B |
Volume | 1,917,899 | 1,443,075 |
Sector | Broad Market / Factor | Health |
52-Week High | $65.59 | $32.91 |
52-Week Low | $50.48 | $23.81 |
Typical Hold Time | 63 Days | 84 Days |
Enterprise Value | — | $30.07B |
Dividend Yield | — | 4.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $51.64, down 1.11% with a bearish technical signal from moving averages and oscillators. The ETF faces headwinds from China's economic challenges including industrial overcapacity and trade tensions, though corporate profits surged 26% in Q2 2026. Support levels cluster around $51-52 with resistance at $52, indicating consolidation near current levels amid mixed market sentiment.
The outlook remains cautious due to China's macroeconomic pressures and global trade friction, though historical discount to US indices presents potential value. Key risks include export restrictions, protectionism threats, and domestic consumption weakness. Institutional activity shows mixed positioning with recent acquisitions offset by reductions.
PHG trades at $24.30, up 0.62% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operational cash flow of $1.17B. Analyst consensus leans Hold (63.64%) while institutional activity remains active with recent purchases by Bank of America and Arrowstreet Capital.
The outlook balances recovery momentum against technical weakness. Investment opportunity lies in continued earnings improvement and new product launches, while risks include competitive pressures and the bearish technical trend. Debt levels remain manageable with debt-to-asset ratio at 25.44% as of 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
